BxPC-3
BxPC-3 (BxPC3) is a human
cell line used in the study of pancreatic adenocarcinomas
and treatments thereof.
BxPC-3 cells were derived from a 61-year-old female in 1986, and were confirmed to be tumorigenic in athymic nude mice, with moderate differentiation.[1] The cells produce mucin, and exhibit an epithelial morphology.[2] BxPC-3 cells lack a KRAS mutation,[3] though it is commonly found in pancreatic cancers.[4] BcPC-3 cells, along with JoPaca-1 cells, have high expression of cancer stem cell markers.[5]
BxPC-3 has been used in tumorigenicity studies, pancreatic cancer therapy research, and other biomedical applications. The cells have been additionally studied for their
PGE2, which can serve as potential drug targets.[6]
See also
References
- PMID 3754176.
- ^ "ECACC General Cell Collection: BxPC-3". Public Health England. Retrieved 25 June 2018.
- ^ "Cellosaurus BxPC-3 (CVCL_0186)". Cellosaurus. Retrieved 25 June 2018.
- S2CID 40118099.
- PMID 23152778.
- PMID 20418756.